1128-71-8

Usage

Uses

Used in Organic Synthesis:
4-(1,3-Oxazol-5-yl)phenol is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its presence of both an oxazole ring and a hydroxyl group allows for a wide range of chemical reactions, making it a valuable building block in the synthesis of complex organic molecules.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(1,3-Oxazol-5-yl)phenol is used as a starting material for the development of new pharmaceuticals. Its unique structure and functional groups contribute to the design of novel drug candidates with potential therapeutic applications.
Used in Antioxidant Applications:
4-(1,3-Oxazol-5-yl)phenol is used as an antioxidant in various industries, including food, cosmetics, and pharmaceuticals. Its ability to scavenge free radicals and protect against oxidative stress makes it a valuable component in formulations designed to prevent oxidation and extend shelf life.
Used in Antimicrobial Applications:
4-(1,3-Oxazol-5-yl)phenol is also used as an antimicrobial agent, particularly in the development of new antibiotics and antifungal agents. Its potential to inhibit the growth of microorganisms makes it a promising candidate for combating drug-resistant infections.
Used in Agrochemical Development:
4-(1,3-Oxazol-5-yl)phenol is used in the development of new agrochemicals, such as pesticides and herbicides. Its potential to control pests and diseases in agriculture can contribute to increased crop yields and food security.
Used in Materials Science and Nanotechnology:
In the field of materials science, 4-(1,3-Oxazol-5-yl)phenol is used for the development of new materials with unique properties. Its potential applications in nanotechnology include the creation of nanostructures and functional materials with applications in electronics, sensors, and other advanced technologies.
Overall, 4-(1,3-Oxazol-5-yl)phenol is a multifaceted compound with a broad spectrum of applications across various industries, making it a valuable asset in the realm of chemical research and development.

InChI:InChI=1/C9H7NO2/c11-8-3-1-7(2-4-8)9-5-10-6-12-9/h1-6,11H

Upstream product

• 1011-51-4 5-(4-methoxyphenyl)-1,3-oxazole 
• 123-11-5 4-methoxy-benzaldehyde 
• 288-42-6 oxazol 
• 106-41-2 4-bromo-phenol 

Downstream Products

• 53242-58-3 2-hydroxy-5-oxazol-5-yl-benzoic acid 

Relevant academic research and scientific papers

Structure-Activity Relationships of New Natural Product-Based Diaryloxazoles with Selective Activity against Androgen Receptor-Positive Breast Cancer Cells

Targeted therapies for ER+/PR+ and HER2-amplified breast cancers have improved patient survival, but there are no therapies for triple negative breast cancers (TNBC) that lack expression of estrogen and progesterone receptors (ER/PR), or amplification or

Synthesis and biological activity of 5-(4-methoxyphenyl)-oxazole derivatives

5-(4′-Methoxyphenyl)-oxazole (MPO), originally reported as a synthetic compound, was isolated from fungal culture broth as an inhibitor of hatch and growth of Caenorhabditis elegans. Nineteen MPO derivatives were chemically synthesized, but showed no effect on C. elegans hatch and growth. These findings strongly suggested that the whole structure of MPO is essential for anti-C. elegans activity.

Mild palladium-catalyzed regioselective direct arylation of azoles promoted by tetrabutylammonium acetate

A mild, general, and convenient palladium-catalyzed direct arylation of the 5-position of azoles with aryl bromides, efficiently promoted by tetrabutylammonium acetate, is described. 1-Methylpyrazole, oxazole, and thiazole reacted at 70°C in N,N-dimethyla

Synthesis, characterization, and antimicrobial evaluation of oxadiazole congeners

A series of 1,3-oxazole, 1,3-thiazole, isomeric 1,2,4-oxadiazole, 1,3,4-oxadiazole, and 1,2,3,4-tetrazole heterocycles was synthesized. All the compounds shared as a common feature the presence of a 4-hydroxyphenyl substituent. The structures of the synthesized compounds were confirmed by MS, 1H-NMR, and elemental analysis. In vitro antimicrobial activity for all the newly synthesized compounds at concentrations of 200-25 μg/mL was evaluated against Gram+ve organisms such as methicillin-resistant Staphylococcus aureus (MRSA), Gram-ve organisms such as Escherichia coli (E. coli), and the fungal strain Aspergillus niger (A. niger) by the cup plate method. Ofloxacin and ketoconazole (10 μg/mL) were used as reference standards for antibacterial and antifungal activity, respectively. Compounds 15, 16, and 20 showed notable antibacterial and antifungal activities at higher concentrations (200 μg/mL), whereas 17-19 were found to display significant antibacterial or antifungal activity (25-50 μg/mL) against the Gram+ve, Gram-ve bacteria, or fungal cells used in the present study.

CCR5 ANTAGONISTS AS THERAPEUTIC AGENTS

The present invention relates to compounds useful in the treatment of CCR5-related diseases and disorders, for example, useful in the inhibition of HIV replication, the prevention or treatment of an HIV infection, and in the treatment of the resulting acq